OBJECTIVE: To study the effectiveness of MHC genotyping in the assessment of risk for IDDM based on the identification of alleles that are significantly associated with risk for IDDM (DQB1 *0302 and *0201) and protection from it (DQB1 *0602/*0603 and *0301). RESEARCH DESIGN AND METHODS: A long series of 649 index cases of IDDM, together with their healthy siblings and 756 healthy blood donors, was collected in Finland. The samples were analyzed using a large-scale assay procedure that was developed for rapid screening purposes. The method utilizes time-resolved fluorometry to detect the hybridization of lanthanide-labeled allele-specific oligonucleotide probes with amplified gene product. RESULTS: A total of 61.9% of IDDM index cases had high risk (DQB1 *0201/*0302) or moderate risk (DQB1 *0302/x [x meaning DQB1 *0302 or a nondefined allele]) genotypes compared with 14.3% of the reference population. In patients and control subjects, the frequencies of low risk genotypes were 28.0 and 22.1%, respectively, and those of decreased risk genotypes, 10.0 and 63.6%. The relative risk of a *0201/*0302 genotype was 53.5 (31.1-92.8) compared with the decreased risk genotypes (63.6% of controls). The graded risk estimation was equally efficient in assessing the risk of IDDM in siblings of child with IDDM. CONCLUSION: The near-automatic typing procedure developed is attractive for large-scale screening projects, such as diabetes prevention and intervention trials.
OBJECTIVE: To study the effectiveness of MHC genotyping in the assessment of risk for IDDM based on the identification of alleles that are significantly associated with risk for IDDM (DQB1 *0302 and *0201) and protection from it (DQB1 *0602/*0603 and *0301). RESEARCH DESIGN AND METHODS: A long series of 649 index cases of IDDM, together with their healthy siblings and 756 healthy blood donors, was collected in Finland. The samples were analyzed using a large-scale assay procedure that was developed for rapid screening purposes. The method utilizes time-resolved fluorometry to detect the hybridization of lanthanide-labeled allele-specific oligonucleotide probes with amplified gene product. RESULTS: A total of 61.9% of IDDM index cases had high risk (DQB1 *0201/*0302) or moderate risk (DQB1 *0302/x [x meaning DQB1 *0302 or a nondefined allele]) genotypes compared with 14.3% of the reference population. In patients and control subjects, the frequencies of low risk genotypes were 28.0 and 22.1%, respectively, and those of decreased risk genotypes, 10.0 and 63.6%. The relative risk of a *0201/*0302 genotype was 53.5 (31.1-92.8) compared with the decreased risk genotypes (63.6% of controls). The graded risk estimation was equally efficient in assessing the risk of IDDM in siblings of child with IDDM. CONCLUSION: The near-automatic typing procedure developed is attractive for large-scale screening projects, such as diabetes prevention and intervention trials.
Authors: Liisa Uusitalo; Jaakko Nevalainen; Irma Salminen; Marja-Leena Ovaskainen; Carina Kronberg-Kippilä; Suvi Ahonen; Sari Niinistö; Georg Alfthan; Olli Simell; Jorma Ilonen; Riitta Veijola; Mikael Knip; Suvi M Virtanen Journal: Matern Child Nutr Date: 2011-11-08 Impact factor: 3.092
Authors: B C Holm; J Svensson; C Akesson; J Arvastsson; J Ljungberg; K Lynch; S-A Ivarsson; A Lernmark; C M Cilio Journal: Clin Exp Immunol Date: 2006-12 Impact factor: 4.330
Authors: V Parikka; K Näntö-Salonen; M Saarinen; T Simell; J Ilonen; H Hyöty; R Veijola; M Knip; O Simell Journal: Diabetologia Date: 2012-03-23 Impact factor: 10.122
Authors: H E Larsson; K Lynch; B Lernmark; A Nilsson; G Hansson; P Almgren; A Lernmark; S-A Ivarsson Journal: Diabetologia Date: 2005-07-01 Impact factor: 10.122
Authors: E Savilahti; T Ormälä; T Saukkonen; U Sandini-Pohjavuori; J M Kantele; A Arato; J Ilonen; H K Akerblom Journal: Clin Exp Immunol Date: 1999-04 Impact factor: 4.330
Authors: H K Akerblom; S M Virtanen; J Ilonen; E Savilahti; O Vaarala; A Reunanen; K Teramo; A-M Hämäläinen; J Paronen; M-A Riikjärv; A Ormisson; J Ludvigsson; H-M Dosch; T Hakulinen; M Knip Journal: Diabetologia Date: 2005-04-19 Impact factor: 10.122
Authors: L Heino; M Lönnrot; M Knip; A Kupila; S Erkkilä; A Toivonen; P Vähäsalo; J Ilonen; O Simell; H Hyöty Journal: Clin Exp Immunol Date: 2001-12 Impact factor: 4.330
Authors: E Bakhtadze; H Borg; G Stenström; P Fernlund; H J Arnqvist; A Ekbom-Schnell; J Bolinder; J W Eriksson; S Gudbjörnsdottir; L Nyström; L C Groop; G Sundkvist Journal: Diabetologia Date: 2006-05-31 Impact factor: 10.122
Authors: Heli T A Siljander; Satu Simell; Anne Hekkala; Jyrki Lähde; Tuula Simell; Paula Vähäsalo; Riitta Veijola; Jorma Ilonen; Olli Simell; Mikael Knip Journal: Diabetes Date: 2009-09-15 Impact factor: 9.461